LaBrosse Nicole (CIK 1910662) reported 26 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-24). Recent activity: Buy HALO (5,332 shares), Sell HALO (2,876 shares), Buy HALO (6,688 shares), Sell HALO (3,608 shares), Buy HALO (5,093 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 5,332 | $0 |
| 2026-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 2,876 | $204,138 |
| 2026-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 6,688 | $0 |
| 2026-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 3,608 | $254,869 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 5,093 | $0 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 2,747 | $218,222 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 5,329 | $0 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 2,874 | $228,311 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 13,351 | $0 |
| 2026-02-17 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 7,273 | $577,767 |
| 2025-09-23 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 1,913 | $148,889 |
| 2025-09-23 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 314 | $24,702 |
| 2025-09-11 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 11,271 | $136,041 |
| 2025-09-11 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 1,135 | $14,176 |
| 2025-09-11 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 6,760 | $508,960 |
| 2025-09-11 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 13,240 | $1.0M |
| 2025-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 6,688 | $0 |
| 2025-02-24 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 3,601 | $207,958 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 1,254 | $0 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 741 | $43,193 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 17,409 | $0 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 9,400 | $547,926 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 5,093 | $0 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Sell | 2,742 | $159,831 |
| 2025-02-18 | HALOZYME THERAPEUTICS, INC. (HALO) | SVP, CHIEF FINANCIAL OFFICER | Buy | 5,329 | $0 |
Source: SEC Form 4 filings · as of 2026-02-24